KATP channel opener and NO donor, clinically used as antianginal agent. Preferentially activates SUR2B- versus SUR2A-containing KATP channels (EC50 values are 10 and > 500 μM respectively) and causes 1.6-fold increase in cardiac eNOS expression. Displays coronary and peripheral vasodilatory properties, reduces both pre- and after-load, and increases coronary blood flow. Also displays cardioprotective effects, possibly through ischemic preconditioning.